BostonGene, a developer of cutting-edge AI-based models for oncology and immunobiology, has announced a strategic research partnership with Kyoto University, a leading research institution in the fields of medicine and science.
This study supports a multicenter Phase II clinical trial led by Professor Manabu Muto of Kyoto University, evaluating the safety and efficacy of combination therapy using immune checkpoint inhibitors (ICIs) and photodynamic therapy (PDT) in patients with advanced gastrointestinal cancer. This investigator-initiated trial is funded by Meiji Seika Pharma Co., Ltd.
Professor Manabu Muto stated, “By combining PDT and ICI, we aim to improve antitumor effects in patients with limited existing treatment options. BostonGene’s AI-powered molecular and immunoprofiling will deepen our understanding of the tumor microenvironment and enable us to identify characteristics related to long-term clinical efficacy. Ultimately, this will support precise and personalized treatment strategies for patients with advanced cancer.”
BostonGene will integrate genomic, transcriptome, immunological, and clinical data from this study to identify molecular signatures and immune response patterns associated with treatment response and resistance. This will establish a scientific foundation for future patient stratification and combination therapy development.
Yukimasa Shiotsu, Representative Director of BostonGene Japan, stated, “Integrating AI-powered multi-omics analysis into clinical development is essential for accelerating the development of next-generation cancer treatments and reducing risks. Through this partnership, we aim to deepen our understanding of the biological response to ICI and PDT combination therapy and identify the patient groups that will benefit the most.”
The findings from this study are expected to contribute to future clinical trial design, biomarker-based patient selection, and the advancement of the development of combination cancer immunotherapies.
